Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fezolamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A known ✓ | Q03164 | 3/20 | 0.42 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.40 |
| ▸ | PTGIR | P43119 | 1/20 | 0.58 |
| ▸ | BRAF | P15056 | 2/20 | 0.45 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fezolamine SCHEMBL122599 | 1.00 | PTGIR (0.58) | PTGIRBRAFMAPK3MAPK1GAA | |
| Fezolamine SCHEMBL5783220 | 0.90 | PTGIR (0.58) | PTGIRBRAFMAPK3MAPK1MEN1 | |
| Fezolamine SCHEMBL121816 | 0.90 | PTGIR (0.58) | PTGIRBRAFMAPK3MAPK1MEN1 | |
| Fezolamine SCHEMBL11491149 | 0.88 | PTGIR (0.57) | PTGIRBRAFMAPK3MAPK1MEN1 | |
| SCHEMBL1385611 | 0.78 | PTGIR (0.44) | PTGIRBRAFMAPK3MAPK1KDM4E | |
| SCHEMBL11483010 | 0.77 | PTGIR (0.64) | PTGIRGAAMEN1KMT2APTGS2 | |
| Hydrochloric Acid SCHEMBL2579363 | 0.77 | PTGIR (0.43) | PTGIRBRAFMAPK3MAPK1KDM4E | |
| SCHEMBL11484379 | 0.77 | PTGIR (0.56) | PTGIRBRAFMAPK3MAPK1MEN1 | |
| SCHEMBL9877663 | 0.76 | PTGIR (0.47) | PTGIRKDM4EALDH1A1CYP2C19LMNA | |
| Hydrochloric Acid SCHEMBL11491105 | 0.76 | PTGIR (0.54) | PTGIRBRAFMAPK3MAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4106872-A1 | COMPOSITIONS AND METHODS FOR ASSESSING THE EFFICACY OF INHIBITORS OF NEUROTRANSMITTER TRANSPORTERS | Denovo Biopharma LLC (US) | 2022-12-28 | — | — | EP | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-12611418-B2 | Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin | COMPASS PATHFINDER LIMITED (GB) | 2026-04-28 | — | — | US | disclosed |
| US-12612661-B2 | Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters | DENOVO BIOPHARMA, LLC (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250367223-A1 | METHODS FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBIN | COMPASS PATHFINDER LIMITED (GB) | 2025-12-04 | — | — | US | disclosed |
| US-20250360148-A1 | SOLID DISPERSIONS OF PSILOCYBIN | CYBIN IRL LIMITED (IE) | 2025-11-27 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20010023254-A1 | Psychological disorders | CINCINNATI, UNIVERSITY OF | 2001-09-20 | — | — | US | disclosed |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | LUITPOLD PHARMACEUTICALS, INC. | 2001-05-31 | — | — | US | disclosed |
| WO-2000053231-A2 | FATTY ACID-ANTICANCER CONJUGATES AND USES THEREOF | PROTARGA, INC. (US) | 2000-09-14 | — | — | WO | disclosed |
| WO-2000050020-A2 | USE OF SULFAMATE DERIVATIVES FOR TREATING IMPULSE CONTROL DISORDERS | UNIVERSITY OF CINCINNATI (US) | 2000-08-31 | — | — | WO | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| US-5780051-A | Methods and articles of manufacture for nicotine cessation and monitoring nicotine use | DYNAGEN, INC. (US) | 1998-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360148-A1 | SOLID DISPERSIONS OF PSILOCYBIN | HTR2B, HTR2A, HTR2C | MEN1 4465/4885KMT2A 2534/4885HRH1 144/4885 |
| US-12612661-B2 | Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters | SLC6A4, SLC18A2, SLC6A2 | MEN1 3992/4885KMT2A 3669/4885HRH1 3046/4885 |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | FABP7, FFAR2, FFAR4 | MEN1 3479/4885KMT2A 3261/4885HRH1 1088/4885 |
| US-12611418-B2 | Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin | HTR1D, HTR1B, HTR2B | MEN1 912/4885KMT2A 3612/4885HRH1 1126/4885 |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | MEN1 2827/4885KMT2A 1839/4885HRH1 530/4885 |
| US-20010023254-A1 | Psychological disorders | DRD2, DRD3, DRD1 | MEN1 3737/4885KMT2A 1530/4885HRH1 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.